VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Black Diamond Therapeutics, Inc. (BDTX) Total Return Calculator with Dividends Reinvested

Black Diamond Therapeutics, Inc.

Popular:

The total return for Black Diamond Therapeutics, Inc. (BDTX) stock is +91.84% over the past 12 months. So far it's up 13.25% this year. The 5-year total return is -88.96%, meaning $10,000 invested in BDTX stock 5 years ago would be worth $1,104 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in BDTX 1 year ago, it would be worth $19,184 today — you'd have gained $9,184.

With Dividends Reinvested$19,184+91.84%

Price Only (No DRIP)$19,184+91.84%

Period2025-05-06 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in BDTX

1Y$19,184+$9,184 (+91.8%)91.8% CAGR

3Y$14,688+$4,688 (+46.9%)13.7% CAGR

5Y$1,104-$8,896 (-89.0%)-35.6% CAGR

10Y$714-$9,286 (-92.9%)-23.2% CAGR

15Y$714-$9,286 (-92.9%)-16.1% CAGR

20Y$714-$9,286 (-92.9%)-12.4% CAGR

30Y$714-$9,286 (-92.9%)-8.4% CAGR

Black Diamond Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading BDTX total return...

As of 2026-05-06

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+13.25%	—	+13.25%	—	$11,325
1Y	+91.84%	91.84%	+91.84%	—	$19,184
3Y	+46.88%	13.67%	+46.88%	—	$14,688
5Y	-88.96%	-35.65%	-88.96%	—	$1,104
10Y	-92.86%	-23.20%	-92.86%	—	$714
15Y	-92.86%	-16.13%	-92.86%	—	$714
20Y	-92.86%	-12.36%	-92.86%	—	$714
30Y	-92.86%	-8.42%	-92.86%	—	$714

Risk & Highlights

Best Year+52.72%2023

Worst Year-83.47%2021

Max Drawdown-58.32%2025-11-12 → 2026-03-27

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-0.80%	-0.80%	—	+0.41%	-1.2pp
2025	+13.55%	+13.55%	—	+16.64%	-3.1pp
2024	-26.46%	-26.46%	—	+24.00%	-50.5pp
2023	+52.72%	+52.72%	—	+24.81%	+27.9pp
2022	-67.91%	-67.91%	—	-19.95%	-48.0pp

BDTX outperformed the S&P 500 by 60.51pp over the past year (+91.84% vs +31.32%).

Loading summary...

BDTX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
BDTXBlack Diamond Therapeutics, Inc.	$161M	+12.8%	+13.3%	+91.8%	—	+46.9%	-89.0%	-92.9%
KYMRKymera Therapeutics, Inc.	$7.0B	+1.2%	+18.6%	+201.9%	—	+211.0%	+110.5%	+159.4%
NUVLNuvalent, Inc.	$6.9B	+0.5%	+3.4%	+52.9%	—	+176.1%	+456.1%	+456.1%
AUPHAurinia Pharmaceuticals Inc.	$2.1B	+1.5%	+5.8%	+100.1%	—	+45.2%	+31.6%	+552.4%
ERASErasca, Inc.	$3.1B	-36.3%	+203.6%	+772.0%	—	+281.1%	-37.5%	-37.5%
ARVNArvinas, Inc.	$656M	-8.6%	-10.5%	+47.6%	—	-58.4%	-83.8%	-36.1%
MGNXMacroGenics, Inc.	$191M	-5.3%	+87.0%	+104.8%	—	-58.4%	-90.6%	-83.4%
PRMEPrime Medicine, Inc.	$616M	+2.1%	-3.4%	+156.4%	—	-75.9%	-77.8%	-53.6%
CGEMCullinan Therapeutics, Inc.	$903M	+0.5%	+48.1%	+91.0%	—	+57.6%	-48.3%	-49.9%
TYRATyra Biosciences, Inc.	$1.8B	-13.2%	+26.2%	+238.0%	—	+150.4%	+30.0%	+30.0%
RGENRepligen Corporation	$7.1B	+7.5%	-23.5%	-3.6%	—	-19.7%	-32.1%	+379.1%

Compare:BDTX vs KYMR BDTX vs NUVL BDTX vs AUPH BDTX vs KYMR vs NUVL

About BDTX Dividend Returns

Black Diamond Therapeutics, Inc. (BDTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of BDTX over the past year?

Black Diamond Therapeutics, Inc. (BDTX) delivered a return of 91.84% over the past year. Since BDTX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in BDTX be worth today?

A $10,000 investment in Black Diamond Therapeutics, Inc. one year ago would be worth $19,184 today, representing a gain of $9,184.

Q3Does BDTX pay dividends?

Black Diamond Therapeutics, Inc. (BDTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For BDTX, the total return equals the price-only return.

Q4Did BDTX beat the S&P 500?

Yes, Black Diamond Therapeutics, Inc. (BDTX) outperformed the S&P 500 by 60.51 percentage points over the past year. BDTX delivered a total return of 91.84%, compared to the S&P 500's 31.32%. This 60.51pp alpha means investors in BDTX earned more than a passive S&P 500 index fund.

Q5What is BDTX's worst drawdown?

Black Diamond Therapeutics, Inc. (BDTX) experienced a maximum drawdown of -58.32% over the past year, declining from its peak on 2025-11-12 to its trough on 2026-03-27. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is BDTX's long-term total return over 10, 20, or 30 years?

Here are Black Diamond Therapeutics, Inc. (BDTX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -92.9% (-23.2% CAGR) — $10,000 would have grown to $714. Over 20 years: -92.9% total return (-12.4% CAGR) — $10,000 → $714. Over 30 years: -92.9% total return (-8.4% CAGR) — $10,000 → $714. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was BDTX's best and worst year?

Black Diamond Therapeutics, Inc.'s best calendar year was 2023 with a total return of 52.7%. Its worst year was 2021 with a total return of -83.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 136.2 percentage points.